FHD 909
Alternative Names: FHD-909; LY-4050784Latest Information Update: 02 Sep 2024
At a glance
- Originator Foghorn Therapeutics; Lilly Research Centre
- Class Antineoplastics; Small molecules
- Mechanism of Action SMARCA2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 31 Aug 2024 Foghorn Therapeutics plans a phase I trial for FHD 909 in Solid tumours and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA in August 2024 (NCT06561685)
- 31 May 2024 US FDA approves IND application for FHD 909 in Non-small cell lung cancer
- 09 Apr 2024 Pharmacodynamics data from the preclinical studies in Cancer released by Foghorn Therapeutics